drugset / Trial / NCT06272487

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487

Phase 2 Completed 375 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Timeline

Start
2024-02-29
Primary completion
2025-06-19
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilebesiran Unknown Subcutaneous

Indications